Quadrant Biosciences Inc.
United States
23 articles about Quadrant Biosciences Inc.
-
Autism-Focused Life Sciences Company Revolutionizes the Diagnostic Journey for Families Nationwide
1/3/2024
Quadrant Biosciences has reached a new milestone in their quest to provide integrated solutions to families who, for decades, have been navigating a very fractured health system surrounding autism services.
-
New York State Laboratory Approved for Genetic Testing Using Saliva
10/17/2023
Quadrant Laboratories announced that its Syracuse-based lab has been approved by the New York State Department of Health for genetic testing.
-
Patent Awarded for Saliva-Based Test to Help Diagnose Concussion and Predict Duration of Symptoms
11/16/2022
Quadrant Biosciences announced today that the U.S. Patent and Trademark Office (USPTO) has awarded the company and two of its academic partners, the State University of New York Research Foundation and the Penn State Research Foundation, with U.S. Patent No.11,453,914 for the analysis and prediction of mild traumatic brain injury (mTBI) and concussion symptoms.
-
Dr. Funda Suer Joins Quadrant Biosciences as EVP of Clinical Diagnostics and CLIA Laboratory Director
6/1/2022
Quadrant Biosciences Inc., a developer of novel molecular diagnostics, announced that Dr. Funda Suer has joined the company as Executive Vice President of Clinical Diagnostics and CLIA Laboratory Director.
-
Patent Issued for Multiomic Approach to Autism Spectrum Disorder Diagnosis
2/28/2022
Quadrant Biosciences Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued the company and its partners, the SUNY Research Foundation and Penn State Research Foundation, U.S Patent No. 11,242,563 (Analysis of Autism Spectrum Disorder).
-
Molecules in Saliva May Hold the Key to Tracking Improvements in Autism
6/3/2021
Molecules in the saliva may hold promise as a means to track the effectiveness of therapeutic interventions in children with autism spectrum disorder.
-
Autism Biomarkers Could Save Billions in Healthcare Costs According to Recent Study
4/22/2021
The use of accurate biomarkers for detecting autism spectrum disorder could result in saving billions of dollars in healthcare costs, according to a paper recently published in the journal Autism Research.
-
Quadrant Biosciences Receives Breakthrough Device Designation for Novel Autism Saliva Test
4/19/2021
Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test.
-
Quadrant Biosciences Receives FDA Emergency Authorization for New COVID-19 Saliva Test
9/23/2020
Quadrant Biosciences Inc., a developer of epigenetic diagnostic tools, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Clarifi COVID-19 Test Kit by SUNY Upstate Medical and Quadrant Biosciences ("Clarifi COVID-19 Test"), a saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
-
Quadrant Biosciences Launches First Ever Epigenetic Saliva Test for Autism
12/4/2019
Quadrant Biosciences Inc., a developer of novel diagnostic solutions, announced the release of Clarifi ASD™, the first ever epigenetic test for autism spectrum disorder (ASD).
-
Quadrant Biosciences Takes Next Step in the Detection of Autism
6/19/2019
Quadrant Biosciences Inc., a developer of epigenetic diagnostic technologies, has been awarded a $330,000 grant from the National Institutes of Health (NIH).
-
Quadrant Biosciences Recognized as New York Technology Business of the Year
5/7/2019
Quadrant Biosciences Inc. has been awarded the Technology Business of the Year by the New York State Small Business Development Center (SBDC).
-
Saliva-Based RNA Panel Accurately Distinguishes Children with Autism Spectrum Disorder from Non-Autistic Peers, Including Children with Developmental Delays
11/9/2018
Results from multi-institutional research collaboration published in Frontiers in Genetics journal
-
Quadrant Biosciences Teams up With Autism Speaks to Provide Support to Families and Healthcare Providers on the Path from Autism Diagnosis to Early Intervention
11/2/2018
Quadrant Biosciences announced today that they will support Autism Speaks’ mission with funding to expand delivery of reliable information, resources and support through the Autism Speaks Autism Response Team.
-
Quadrant Biosciences to Collaborate on Signature Study of Minocycline Treatment of Autism Spectrum Disorder
10/25/2018
Study will evaluate effectiveness and safety of a medicine that has shown potential in easing autism symptoms
-
US All Star Federation Cheer Organization Partners with Quadrant Biosciences to Offer Brain Health Assessments
8/10/2018
Best-in-Class ClearEdge brain health assessments now available to USASF members
-
Quadrant Biosciences Partners with Leading Edge Genomic Testing Company Admera Health
8/8/2018
Rising companies in diagnostic space form strategic partnership
-
ClearEdge Wins 2018 Sports Medicine Technology Award
8/1/2018
Quadrant Biosciences brain health toolkit recognized for innovation
-
Researchers Discover Key Link to Understanding Sleep Disorders
7/19/2018
Researchers have discovered a key link to potentially understanding sleep disorders in children, according to a study just published in the journal PLOS One.
-
Quadrant Biosciences Inc. and ChoiceOne/MedSpring Urgent Care Enter Partnership to Offer Unique Brain Health Assessments
6/4/2018
National Urgent Care organization to begin roll out of novel brain health assessment